Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Pamela Esposito Sells 13,500 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Pamela Esposito sold 13,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Kymera Therapeutics Stock Performance

Shares of Kymera Therapeutics stock traded down $1.18 during trading hours on Tuesday, reaching $47.30. The company’s stock had a trading volume of 327,736 shares, compared to its average volume of 627,109. The company has a market capitalization of $2.90 billion, a P/E ratio of -19.31 and a beta of 2.22. The stock’s fifty day simple moving average is $44.57 and its two-hundred day simple moving average is $38.89. Kymera Therapeutics, Inc. has a one year low of $9.60 and a one year high of $50.19.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.10. The business had revenue of $25.60 million for the quarter, compared to analysts’ expectations of $12.55 million. Kymera Therapeutics had a negative net margin of 178.27% and a negative return on equity of 28.88%. The firm’s revenue for the quarter was up 55.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.67) EPS. As a group, research analysts forecast that Kymera Therapeutics, Inc. will post -2.87 earnings per share for the current year.

Institutional Investors Weigh In On Kymera Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Quest Partners LLC bought a new stake in Kymera Therapeutics in the 4th quarter worth about $78,000. Comerica Bank grew its holdings in shares of Kymera Therapeutics by 13.7% in the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after acquiring an additional 400 shares in the last quarter. Public Employees Retirement Association of Colorado bought a new position in shares of Kymera Therapeutics in the second quarter valued at approximately $139,000. Ameritas Investment Partners Inc. increased its position in shares of Kymera Therapeutics by 7.8% during the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock valued at $164,000 after acquiring an additional 295 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in Kymera Therapeutics during the second quarter worth $201,000.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on KYMR shares. HC Wainwright restated a “buy” rating and issued a $46.00 target price on shares of Kymera Therapeutics in a report on Monday, June 17th. Leerink Partners reissued an “outperform” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research note on Monday, September 9th. Morgan Stanley raised their target price on Kymera Therapeutics from $34.00 to $45.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 14th. Wolfe Research raised Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price target on the stock in a research note on Monday, August 26th. Finally, Wells Fargo & Company increased their price target on Kymera Therapeutics from $30.00 to $38.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. Four investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.67.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.